These solutions are delivered in a double chamber bag. One chamber contains the alkaline lactate solution, the other chamber contains the acidic glucose-based electrolyte solution. Mixing of both solutions by opening the middle seam between the two chambers results in the neutral ready-to-use solution.

Composition: 1 litre of the neutral ready-to-use solution contains:									
Active substances	balance	balance	balance	balance	balance	balance			
in g/l	1.5% glucose	2.3% glucose	4.25% glucose	1.5% glucose	2.3% glucose	4.25% glucose			
	1.75 mmol/l calcium	1.75 mmol/l calcium	1.75 mmol/l calcium	1.25 mmol/l calcium	1.25 mmol/l calcium	1.25 mmol/l calcium			
Sodium chloride	5.640	5.640	5.640	5.640	5.640	5.640			
Sodium lactate	3.925	3.925	3.925	3.925	3.925	3.925			
(as sodium lactate solution)									
Calcium chloride dihydrate	0.2573	0.2573	0.2573	0.1838	0.1838	0.1838			
Magnesium chloride hexahydrate	0.1017	0.1017	0.1017	0.1017	0.1017	0.1017			
Glucose, anhydrous	15	22.73	42.5	15	22.73	42.5			
(as glucose monohydrate)									

Active substances in mmol/l	<i>balance</i> 1.5% glucose	<i>balance</i> 2.3% glucose	<i>balance</i> 4.25% glucose	<i>balance</i> 1.5% glucose	<i>balance</i> 2.3% glucose	<i>balance</i> 4.25% glucose
	1.75 mmol/l calcium	1.75 mmol/l calcium	1.75 mmol/l calcium	1.25 mmol/l calcium	1.25 mmol/l calcium	1.25 mmol/l calcium
Na <sup>+</sup>	134	134	134	134	134	134
Ca <sup>2+</sup>	1.75	1.75	1.75	1.25	1.25	1.25
Mg <sup>2+</sup>	0.5	0.5	0.5	0.5	0.5	0.5
CI <sup>-</sup>	101.5	101.5	101.5	100.5	100.5	100.5
Lactate	35	35	35	35	35	35
Glucose	83.2	126.1	235.8	83.2	126.1	235.8
Theoretical osmolarity (mosm/l)	358	401	511	356	399	509

**Excipients:** Water for injections, hydrochloric acid, sodium hydroxide, sodium hydrogen carbonate.

**Indications:** End-stage (decompensated) chronic renal failure of any origin treated with peritoneal dialysis.

Contraindications: Solution related: Solutions with 1.5%/2.3%/4.25% glucose, 1.75 mmol/l calcium: Severe hypokalaemia and severe hypercalcaemia. Solutions with 1.5%/2.3%/4.25% glucose, 1.25 mmol/l calcium: Severe hypokalaemia and severe hypocalcaemia. Solutions with 4.25% glucose: Additionally hypovolaemia and arterial hypotension. Treatment related: Recent abdominal surgery or injury, burns, hernia, inflammatory abdominal skin reaction (dermatitis), inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticulitis), peritonitis, non-healing weeping wounds (abdominal fistulae), intra-abdominal tumours, intestinal obstruction (lleus), lung diseases (especially pneumonia), metabolic disorders (lactic acidosis), generalised blood poisoning (sepsis), extreme weight loss (cachexia), particularly when adequate nutrition is impossible, in cases of accumulation of uraemic toxins in the blood (uraemia) the elimination of which can not be managed by peritoneal dialysis, very high levels of fat in the blood (hyperlipidaemia).

**Undesirable effects:** *Infections:* Peritonitis (very common); skin exit site and tunnel infections (very common); in very rare cases sepsis. *Disorders of the hormone balance for solutions containing 1.25 mmol/l calcium:* Overactivity of the parathyroid gland with potential disorders of the bone metabolism. *Metabolism and nutrition disorders:* Increased blood sugar and fat levels; increase in body

weight due to the continuous uptake of glucose from the peritoneal dialysis solution. Cardiac and vascular disorders: Frequent pulse; decreased or increased blood pressure. Respiratory disorders: Shortness of breath due to elevation of the diaphragm, shoulder pain. Gastrointestinal disorders: Diarrhoea; constipation; hernia (very common); abdominal distension and sensation of fullness. Renal disorders: Electrolyte disturbances, e.g. decreased potassium levels (very common), increased calcium levels in combination with an increased calcium uptake, e.g. by the administration of calcium containing phosphate binders or decreased calcium levels for solutions containing 1.25 mmol/l calcium. General disorders and administration/catheter site conditions: General malaise; redness, swellings, exudations, crusts and pain at the catheter exit site; dizziness; oedema; disturbances in hydration indicated either by a rapid decrease (dehydration) or increase (overhydration) in body weight. Severe dehydration might occur when using solutions of higher glucose concentration. Peritoneal dialysis procedure related disorders: Cloudy effluent; in- and outflow disturbances of the dialysis solution.

**Warnings and Precautions:** Do not use unless solution is clear and container undamaged. For single use only. Any unused portion of the solution is to be discarded. Do not use before mixing both solutions. The ready-to-use solution must be used within 24 hours after mixing. Do not store below  $4^{\circ}$ C.

Date: December 2006

Fresenius Medical Care Deutschland GmbH 61346 Bad Homburg v.d.H., Germany

